• Non Drug Treatment of Hypertension: Literature Updates & What Works

    Original Date: May 18, 2013
    Presenter: Kasra Pournadeali, ND

    1.5 general CEUs for NDs approved by OBNM
  • Cardiovascular Disorders in Women

    Original Date: May 18, 2013
    Presenter: Beverly Yates, ND

    1.5 general CEUs for NDs approved by OBNM

    Important issues that affect treatment outcomes for women with CV disorders are covered in this presentation. The reasons for missed diagnosis of CV diseases in women are revealed, along with the impact this has on treatment outcomes. Case studies offer treatment plan strategies, including stand-alone natural therapies or integrative medical approaches for the successful treatment of female patients with CV disorders. Special considerations are discussed for specific co-morbidities, e.g. dyslipidemia, morbid obesity, Type 2 diabetes, hypertension and common sequelae of pharmaceuticals used for CV interventions.
  • Advanced Cardiovascular Risk Assessment Using Imaging and Novel Biomarkers

    Original Date: May 18, 2013
    Presenter: Steve Parcell, ND

    1.5 general CEUs for NDs approved by OBNM

    Dr. Parcell introduces this talk by explaining why the standard of care for heart attack prevention is not adequate in the United States. He reviews the important biomarkers and imaging technologies that have become available in recent years. Then Dr. Parcell explains how these results can be combined to create a more accurate assessment of a patient’s real risk. He discusses how to use these test results to guide the selection of treatments and gain compliance with treatment. Most importantly Dr. Parcell provides instruction about how to prevent heart attacks and how to stabilize or reverse arterial plaque.
  • Coronary Artery Disease: What Every Physician Needs to Know

    Original Date: May 18, 2013
    Presenter: Peter Banitt, MD

    1.5 CEUs (1.0 general and 0.5 pharm) for NDs approved by OBNM

    Coronary artery disease (CAD) is an extremely important medical condition as heart disease is the leading cause of death in the United States. Many factors contribute to the development of coronary artery disease, and there are many treatment options for patients with this diagnosis.

    Cardiologist Peter Banitt reviews etiology, risk factors and pathophysiology of CAD, and offer practical advice for practicing primary care providers. He explains which patients will benefit from statin drugs. He discusses which patients need a stent versus who could be treated with only medications. Moreover, Dr. Banitt explains the likelihood that your patient will have a cardiac event in the next 10 years.
  • Arrhythmias, Valvular Disorders and Cardiomyopathy

    Original Date: May 18, 2013
    Presenter: Ahvie Herskowitz, MD

    1.5 general CEUs for NDs approved by OBNM

    As our patients’ ability to cohabitate with stress, nutritional and environmental challenges coronary and non-coronary cardiovascular disease have exploded in incidence. Dr. Herskowitz explores different causes for this increase and pathophysiology and treatment paradigms both western and alternative for atrial fibrillation, valvular disorders, cardiomyopathy and cardiac infections.
  • Endothelial Dysfunction: A Shared Mechanism of Dysfunction in Metabolic and Coronary Diseases

    Original Date: May 19, 2013
    Presenter: Ryan Bradley, ND, MPH

    1.5 general CEUs for NDs approved by OBNM

    This presentation updates viewers on the concept of endothelial dysfunction; its pathophysiology; its importance in disease risk beyond cardiovascular disease; and integrative treatment approaches. Endothelial dysfunction is a common, cumulative pathophysiological mechanism that occurs secondary to dietary and environmental exposures, and occurs in nearly every vascular bed. This presentation teaches viewers about the importance of improving endothelial cell function to promote health beyond just cardiovascular disease. Recent evidence implicates endothelial dysfunction (ED) in the progression of metabolic disease, asthma, chronic kidney disease, sexual function, autoimmune disease, neurodegenerative disease, and coronary artery disease.
  • Naturopathic Use of Antihypertensives: When Non-Drug Options Fail

    Original Date: May 19, 2013
    Presenter: Kasra Pournadeali, ND

    1.5 Pharmacy CEUs for NDs approved by OBNM

    Cardiology Expert, Dr. Kasra Pournadeali returns to review “naturopathic” application of antihypertensive drugs, and JNC guidelines for their use. A great presentation to review when you are considering a prescription medication for patients who need more than lifestyle change, therapeutic nutrition, or plant medicines.

    Learning Objectives:
    • The viewer will be able to choose antihypertensives based on most recent guidelines
    • The viewer will be able to choose antihypertensives based on the patient’s other diseases
    • The viewer will be able to choose antihypertensives based on a whole person perspective
  • New Horizons in Cardiovascular Exercise Rehabilitation

    Original Date: May 19, 2013
    Presenter: Marty Milner, ND

    1.5 general CEUs for NDs approved by OBNM

    Dr. Milner discusses the critical management of therapeutic exercise in the cardiovascular patient. Exercise in this population is often challenging and complicated by the combination of poly pharmacy and comorbidities which may alter exercise outcomes. The discussion includes general cardiac rehabilitation guidelines followed by training in the use of:
    • aerobic exercise tolerance testing
    • aerobic exercise prescription guidelines
    • oxygen multistep therapy
    • nutrient packets in advance of exercise to enhance performance
    • interval training
    Dr. Milner has spent his entire 30 years of clinical practice refining these exercise protocols and enjoys sharing his perspectives.
  • Integrative Management of Heart Failure

    Original Date: May 19, 2013
    Presenter: Jeremy Mikolai, ND

    1.5 CEUs (1.0 general and 0.5 pharm) for NDs approved by OBNM

    Dr. Mikolai discusses the evidence-informed use of complementary and alternative (CAM) therapeutics in the management several types of heart failure. Systolic failure, diastolic failure, ischemic cardiomyopathy, atrial fibrillation and several types of valvular disease are all addressed as potential causes of heart failure; the indications, applications, and contraindications for common CAM therapies in each of these circumstances will be discussed.
  • Plant Sterols and Heart Health

    Original Date: May 19, 2013
    Presenter: Peter Jones, PhD

    1.5 general CEUs for NDs approved by OBNM